TY - JOUR
T1 - Whole-exome sequencing of salivary gland mucoepidermoid carcinoma
AU - Kang, Hyunseok
AU - Tan, Marietta
AU - Bishop, Justin A.
AU - Jones, Siân
AU - Sausen, Mark
AU - Ha, Patrick K.
AU - Agrawal, Nishant
N1 - Funding Information:
We thank our patients for their courage and generosity and R. Yonescu for technical assistance. This work was supported by NIH/NIDCR grant DE023218 (N. Agrawal) and NIH/NIDCR Specialized Program of Research Excellence grant DE019032 (N. Agrawal). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Publisher Copyright:
©2016 AACR.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Purpose: Mucoepidermoid carcinoma (MEC) is the most common salivary gland malignancy. To explore the genetic origins of MEC, we performed systematic genomic analyses of these tumors. Experimental Design: Whole-exome sequencing and gene copy-number analyses were performed for 18 primary cancers with matched normal tissue. FISH was used to determine the presence or absence of the MECT1-MAML2 translocation in 17 tumors. Results: TP53 was the most commonly mutated gene in MEC (28%), and mutations were found only in intermediate- and high-grade tumors. Tumors with TP53 mutations had more mutations overall than tumors without TP53 mutations (P = 0.006). POU6F2 was the second most frequently mutated gene, found in three low-grade MECs with the same in-frame deletion. Somatic alterations in IRAK1, MAP3K9, ITGAL, ERBB4, OTOGL, KMT2C, and OBSCN were identified in at least two of the 18 tumors sequenced. FISH analysis confirmed the presence of the MECT1-MAML2 translocation in 15 of 17 tumors (88%). Conclusions: Through these integrated genomic analyses, MECT1-MAML2 translocation and somatic TP53 and POU6F2 mutations appear to be the main drivers of MEC.
AB - Purpose: Mucoepidermoid carcinoma (MEC) is the most common salivary gland malignancy. To explore the genetic origins of MEC, we performed systematic genomic analyses of these tumors. Experimental Design: Whole-exome sequencing and gene copy-number analyses were performed for 18 primary cancers with matched normal tissue. FISH was used to determine the presence or absence of the MECT1-MAML2 translocation in 17 tumors. Results: TP53 was the most commonly mutated gene in MEC (28%), and mutations were found only in intermediate- and high-grade tumors. Tumors with TP53 mutations had more mutations overall than tumors without TP53 mutations (P = 0.006). POU6F2 was the second most frequently mutated gene, found in three low-grade MECs with the same in-frame deletion. Somatic alterations in IRAK1, MAP3K9, ITGAL, ERBB4, OTOGL, KMT2C, and OBSCN were identified in at least two of the 18 tumors sequenced. FISH analysis confirmed the presence of the MECT1-MAML2 translocation in 15 of 17 tumors (88%). Conclusions: Through these integrated genomic analyses, MECT1-MAML2 translocation and somatic TP53 and POU6F2 mutations appear to be the main drivers of MEC.
UR - http://www.scopus.com/inward/record.url?scp=85010223568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010223568&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-16-0720
DO - 10.1158/1078-0432.CCR-16-0720
M3 - Article
C2 - 27340278
AN - SCOPUS:85010223568
SN - 1078-0432
VL - 23
SP - 283
EP - 288
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 1
ER -